Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 11000
Summary
- Conditions
- Corona Virus Infection
- Critical Illness
- Cytokine Release Syndrome
- Type
- Observational
- Design
- Observational Model: OtherTime Perspective: Prospective
Participation Requirements
- Age
- Between 14 years and 125 years
- Gender
- Both males and females
Description
This study will provide further insight whether anti-IL6 alone provide same efficacy and clinical outcome with reasonable side effects profile compared to anti-IL6 + corticosteroid and might serve as a corticosteroid sparing agents in COVID-19 patient with cytokine storms. Data elements will be retr...
This study will provide further insight whether anti-IL6 alone provide same efficacy and clinical outcome with reasonable side effects profile compared to anti-IL6 + corticosteroid and might serve as a corticosteroid sparing agents in COVID-19 patient with cytokine storms. Data elements will be retrieved from VIRUS registry which is a prospective, non-interventional, multi-center, multi-national observational cross sectional study
Tracking Information
- NCT #
- NCT04486521
- Collaborators
- Society of Critical Care Medicine
- Investigators
- Principal Investigator: Marwa Amer, PharmD,BCPS, BCCCP King Faisal Specialist Hospital and Research Center- Riyadh Principal Investigator: Mohammed Bawazeer, MD,FRCSC,FACS King Faisal Specialist Hospital and Research Center- Riyadh
Get Well Soon